What is China’s real potential for R&D and innovative “breakthrough” products? February 18 article by Andrew Ward in London and Patti Waldmeir in Shanghai in Financial Times reported on recent advances by Chinese drug developers in raising funds that have piqued the interest of investors despite the country’s economic upset this past summer. China has long been on the “big potential” list for investors and drug developers looking to expand market reach. The article adds to the enthusiasm, pointing to a new generation of biotech companies who are aggressively competing for funds to “ come up with the next ‘made in China’ medicine.”
BeiGene’s USD 158 million IPO and Hutchison China MediTech plans for a NYSE listing, and Jiangsu Hansoh and Simcere’s plans for IPOs by year-end, are just a few examples mentioned in the FT article as benchmarks in China’s timeline to move from manufacturing to innovation. Global developers continue bringing R&D to China, and cross border alliances between big pharma and China companies remain the backbone of alliances, but the most interesting alliances are with prominent young companies like WuXi AppTec who are providing “outsourced research and manufacturing to foreign and local pharma groups.”
Innovation takes time, and money. Like any new developer’s market, China’s still needs time to mature. But all signs look positive that there is real heft behind the hype, which means real opportunities for potential collaborations.
Click here to read the full Financial Times article. Financial Times is a subscription based news source.
To access China’s growing potential, attend ChinaBio® Partnering Forum, the premier life science partnering event in China, May 18–19, 2016.